|1.||Freitas, Kelen: 2 articles (02/2013 - 01/2013)|
|2.||Ivy Carroll, F: 1 article (02/2013)|
|3.||Imad Damaj, M: 1 article (02/2013)|
|4.||Ghosh, Sudeshna: 1 article (02/2013)|
|5.||Lichtman, Aron H: 1 article (02/2013)|
|6.||Damaj, M Imad: 1 article (01/2013)|
|7.||Carroll, F Ivy: 1 article (01/2013)|
02/01/2013 - "Our results indicate that the type II α7 nAChRs PAM PNU-120596, but not the type I α7 nAChRs PAM NS1738, shows significant anti-edematous and anti-allodynic effects in inflammatory and CCI pain models in mice."
01/01/2013 - "Our results indicate that type II α7 nAChR PAM PNU-120596, but not type I α7 nAChR PAM NS1738, shows significant antinociception effects in persistent pain models in mice."
02/01/2013 - "We tested two types of PAMS, type I (NS1738) and type II (PNU-120596) in carrageenan-induced inflammatory pain and chronic constriction injury (CCI) neuropathic pain models. "
01/01/2013 - "Testing type I [N-(5-chloro-2-hydroxyphenyl)-N'-[2-chloro-5-(trifluoromethyl)phenyl] (NS1738)] and type II [1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl) (PNU-120596)] α7 nAChR PAMs in acute and persistent pain, we found that, although neither reduced acute thermal pain, only PNU-120596 dose-dependently attenuated paw-licking behavior in the formalin test. "
|2.||Neuralgia (Stump Neuralgia)
|1.||1- (5- chloro- 2,4- dimethoxyphenyl)- 3- (5- methylisoxazol- 3- yl)urea
|5.||tranilast (N 5')